Bell R H, Pour P M
Cancer Lett. 1987 Feb;34(2):221-30. doi: 10.1016/0304-3835(87)90014-0.
To examine the role of diabetes in pancreatic cancer, 4 groups of Chinese hamsters--2 from genetically diabetic and 2 from non-diabetic lines--were treated with N-nitrosobis(2-oxo-propyl)amine (BOP) at different dose levels and intervals. In one group (referred to as the VA group), BOP was given weekly at a 5 mg/kg body wt. level for 18 or 23 weeks, whereas the other group (the EP group) received a weekly dose of 2.5 mg/kg body wt. for life. Except for diet and experimental design, all other laboratory conditions were similar in the two institutions. No VA hamster developed tumors. Three of 22 non-diabetic EP hamsters (but none of the diabetic hamsters) developed pancreatic hyperplastic and neoplastic lesions, comprising ductular cell adenomas (3 hamsters), carcinoma in situ (1 hamster), a well-differentiated adenocarcinoma (1 hamster), and a poorly differentiated adenocarcinoma (1 hamster) with regional lymph node metastases. In addition, over 50% of the EP hamsters had neoplasms for which the incidences and morphology did not vary between diabetic and non-diabetic groups or between the sexes. These were primarily of the liver (cholangiomas), lungs (adenomas) and skin (trichoepitheliomas, squamous cell carcinomas). The differing carcinogenic response of the two hamster groups to BOP apparently is not related to the total BOP dose, but rather to other factors, including the length of observation time.
为研究糖尿病在胰腺癌中的作用，将4组中国仓鼠（2组来自遗传性糖尿病品系，2组来自非糖尿病品系）以不同剂量水平和间隔给予N-亚硝基双（2-氧代丙基）胺（BOP）。在一组（称为VA组）中，每周以5mg/kg体重的剂量给予BOP，持续18或23周，而另一组（EP组）则终身每周接受2.5mg/kg体重的剂量。除饮食和实验设计外，两个机构的所有其他实验室条件均相似。没有VA仓鼠发生肿瘤。22只非糖尿病EP仓鼠中有3只（但糖尿病仓鼠中没有）发生了胰腺增生性和肿瘤性病变，包括导管细胞腺瘤（3只仓鼠）、原位癌（1只仓鼠）、高分化腺癌（1只仓鼠）和低分化腺癌（1只仓鼠）伴区域淋巴结转移。此外，超过50%的EP仓鼠患有肿瘤，其发病率和形态在糖尿病组和非糖尿病组之间或性别之间没有差异。这些肿瘤主要发生在肝脏（胆管瘤）、肺（腺瘤）和皮肤（毛发上皮瘤、鳞状细胞癌）。两组仓鼠对BOP的致癌反应不同，显然与BOP的总剂量无关，而是与其他因素有关，包括观察时间的长短。
